Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...
3don MSN
Innate Pharma SA (IPHA) announced that the FDA has granted Breakthrough Therapy Designation to lacutamab for treating adults ...
The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback